Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ CoreWeave initiated at Hold despite soaring revenue due to high leverage, capex: Truist (SeekingAlpha) +++ COREWEAVE Aktie -4,45%

HENGRUI Aktie

 >HENGRUI Aktienkurs 
8.225 EUR    (Tradegate)
Ask: 8.35 EUR / 718 Stück
Bid: 8.1 EUR / 744 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
HENGRUI Aktie über LYNX handeln
>HENGRUI Performance
1 Woche: +9,7%
1 Monat: +4,6%
3 Monate: -18,0%
6 Monate: +30,2%
1 Jahr: 0%
laufendes Jahr: +8,3%
>HENGRUI Aktie
Name:  JIANGSU HENGRUI PHARMACEUTICALS
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  CNE100006XS6 / A41984
Symbol/ Ticker:  0BO (Frankfurt)
Kürzel:  FRA:0BO, ETR:0BO, 0BO:GR
Index:  -
Webseite:  https://www.hengrui.com/
Profil:  Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a lea..
>Volltext..
Marktkapitalisierung:  48221.49 Mio. EUR
Unternehmenswert:  43437.33 Mio. EUR
Umsatz:  3672.28 Mio. EUR
EBITDA:  -
Nettogewinn:  884.23 Mio. EUR
Gewinn je Aktie:  -
Schulden:  9.88 Mio. EUR
Liquide Mittel:  4838.87 Mio. EUR
Operativer Cashflow:  1429.69 Mio. EUR
Bargeldquote:  5.16
Umsatzwachstum:  12.6%
Gewinnwachstum:  29.39%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  HENGRUI
Letzte Datenerhebung:  06.01.26
>HENGRUI Kennzahlen
Aktien/ Unternehmen:
Aktien: 258.2 Mio. St.
Frei handelbar: 94.55%
Leerverk. Aktien: -
Rückkaufquote: 0.06%
Mitarbeiter: 20238
Umsatz/Mitarb.: 0.16 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 6.47%
Bewertung:
KGV: -
KGV lG: 52.3
KUV: -
KBV: 7.75
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 87.67%
Gewinnmarge: 24.08%
Operative Marge: 24.69%
Managementeffizenz:
Gesamtkaprendite: 12.58%
Eigenkaprendite: 14.21%
>HENGRUI Peer Group

Es sind 98 Aktien bekannt.
 
05.01.26 - 05:45
Research: Daiwa Names INNOVENT BIO as Top Pick Alongside HENGRUI PHARMA w/ TP Lifted to HKD112 (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
04.12.25 - 06:15
H Shrs: HSI Leaps 48 Pts at Midday; Robotics Concept Hyped Up (AAStocks)
 
The HSI concluded the midday up 48 points or 0.2% at 25,809. The HSCEI rose 34 points or 0.4% to 9,062. The HSTECH climbed 32 points or 0.6% to 5,567. The total half-day turnover for the market amounted to HKD92.278 billion.In the FTSE China 50 Index review, CHINAHONGQIAO (01378.HK), CATL (03750.HK), and HENGRUI PHARMA (01276.HK......
04.12.25 - 03:15
H Shrs: HSI Opens 43 Pts Higher; ZIJIN MINING, CHINAHONGQIAO Rally; LI AUTO-W Recedes (AAStocks)
 
The HSI opened 43 points or 0.2% higher at 25,804. The HSCEI climbed 23 points or 0.3% to 9,051. The HSTECH rose 11 points or 0.2% to 5,546.In the FTSE China 50 Index review, CHINAHONGQIAO (01378.HK), CATL (03750.HK), and HENGRUI PHARMA (01276.HK) were included, while CSC (06066.HK), GWMOTOR (02333.HK), and LI AUTO-W (02015.HK) ......
04.12.25 - 02:30
FTSE China 50 Index Quarterly Review Includes CHINAHONGQIAO, CATL, HENGRUI PHARMA (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
04.12.25 - 01:30
Ming Yu seeks a share of the drug sector limelight (Bamboo Works)
 
Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO Key Takeaways:    By Molly Wen A biotech founded by a former executive of Hengrui Pharma (600276.SH; 1276.HK) will be looking to bask in a halo effect..... The post Ming Yu seeks a share of the drug sector limelight appeared first on Bamboo Works....
25.11.25 - 03:15
S&P Global Mkt Intelligence Lists Top 10 Most Shorted HK Stocks Recently (AAStocks)
 
Stock Name│Change in Past 7 Days %│Short Interest %│Price Change in Past 7 Days %HENGRUI PHARMA (01276.HK) | +1.47% | 20.89% | -7.89%CHINA VANKE (02202.HK) | +1.38% | 17.46% | -3.68%ZTE (00763.HK) | -1.77% | 15.43% | -7.13%COSCO SHIP HOLD (01919.HK) | +0.21% | 14.19% | -4.87%CATL (03750.HK)│-2.98%│1......
18.11.25 - 09:00
S&P Global Mkt Intelligence Lists Top 10 Most Shorted HK Stocks Recently (AAStocks)
 
Stock Name│Change in Past 7 Days %│Short Interest %│Price Change in Past 7 Days %HENGRUI PHARMA (01276.HK) | 1.64% | 19.42% | 2.36%ZTE (00763.HK) | -0.32% | 17.20% | -2.98%CHINA VANKE (02202.HK) | 0.42% | 16.08% | 1.16%CATL (03750.HK) | -0.05% | 15.98% | -2.95%COSCO SHIP HOLD (01919.HK) | -0.12% | 13.98% | -0.2......
11.11.25 - 04:45
S&P Global Market Intelligence Lists Top 10 Shorted H Shrs Recently (AAStocks)
 
S&P Global Market Intelligence listed the top ten most shorted stocks in Hong Kong as of last Friday (7th). The data was calculated based on securities and finance datasets from S&P Global Market Intelligence. Stock Name | Change in Past 7 Days (%) | Short Selling Ratio (%) | Price Change in Past 7 Days (%)HENGRUI PHARMA......
27.10.25 - 12:36
Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion (PR Newswire)
 
SHANGHAI, Oct. 27, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK) reported revenue of RMB23.20 billion for the first three quarters of 2025, up 14.85% year-on-year. Net profit attributable to shareholders was RMB5.75 billion, increased by 24.50% compared with the same period......
20.10.25 - 14:18
Corporate News: Hengrui Pharma (EQS)
 
Live vom ESMO | Hengrui präsentiert erstmals einen Messestand mit wegweisenden Daten und zeigt die aufkommende Innovationskraft der Pharmaindustrie...
20.10.25 - 09:21
Corporate News: Hengrui Pharma (EQS)
 
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma’s Emerging Innovation Power...
20.10.25 - 08:24
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma′s Emerging Innovation Power (PR Newswire)
 
BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui......
14.10.25 - 07:15
Research: Daiwa Initiates Coverage on HENGRUI PHARMA w/ Rating Hold, TP HKD86 (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
30.09.25 - 05:30
Research: UBS Ratings/ TPs on CN Pharmas (Table) (AAStocks)
 
Stock | Rating | TP (HKD)HENGRUI PHARMA (01276.HK) | Buy | 97.8 HANSOH PHARMA (03692.HK) | Buy | 48.2 SINO BIOPHARM (01177.HK) | Buy | 12.23SBIO (01530.HK) | Buy | 41 CSPC PHARMA (01093.HK) | Buy -> Neutral | 10 SIMCERE PHARMA (02096.HK) | Buy | 16.3HENGRUI PHARMA (600276.SH) | Buy | RMB78.6 HUADONG MEDICINE (000963.SZ) | Buy......
25.09.25 - 06:54
China′s Hengrui gets boost from fifth drug-licensing deal of year (SCMP)
 
Shares in Jiangsu Hengrui Pharmaceuticals, China's largest drug maker by market value, got a boost on Thursday after it announced its fifth licensing deal of the year, widening its access to the key emerging market of India. The Shanghai-listed company, which went public in Hong Kong in May and raised HK$9.9 billion (US$1.26 billion), struck a deal with Glenmark Specialty of Mumbai-based Glenmark Pharmaceuticals, it said in a stock exchange filing late on Wednesday. The agreement was part of an......
18.09.25 - 12:15
HENGRUI PHARMA Receives CN Approval for SHR-1139 Injection Clinical Trial (AAStocks)
 
HENGRUI PHARMA (01276.HK) announced that its subsidiary, Guangdong Hengrui Pharmaceutical Co., Ltd. (literal translation of "廣東恆瑞醫藥有限公司"), had received an approval from China's National Medical Products Administration for the SHR-1139 injection c......
18.09.25 - 10:15
Full-day Takeaway: HSI Down 363 pts; HSTI Down 63 pts; HKEX Down over 3%; SMIC, HKBN, SHOUCHENG, HENGRUI PHARMA, SANHUA Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI dropped 363 pts or 1.4% to 26,544. HSTI dropped 63 pts or 1.0% to 6,271. HSCEI fell 140 pts or 1.5% to 9,456. Market turnover reached $413.31 billion.Active Heavyweights:HKEX (00388.HK) closed at $444, down 3.1%TENCENT (00700.HK) closed at $642, down 2.9%PING AN (02318.HK) closed at $54.25, down 2.7%BABA (09988.HK)......
17.09.25 - 11:45
HENGRUI PHARMA's Injection for Chronic Hepatitis B Treatment Included in Proposed Breakthrough Therapy List (AAStocks)
 
HENGRUI PHARMA (01276.HK) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd. (literal translation of "福建盛迪醫藥有限公司"), had its HRS-5635 injection included in the proposed breakthrough therapy list published by the Center for Drug Eva......
09.09.25 - 05:30
Research: Nomura Raises HENGRUI PHARMA's TP to HKD94.54; Rating Kept Buy (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
09.09.25 - 04:45
Research: Citi: '15th 5-Yr Plan' to Act as Catalyst; HENGRUI PHARMA/ SUNNY OPTICAL/ ASMPT New Top Picks (AAStocks)
 
The results performance of Chinese companies in 1H25 was roughly in line, Citi's research report wrote. In view of China's 1H25 GDP growth beat, but with PPI and CPI miss, the broker believed that the authorities will continue to advance supply-side reforms to boost CPI and PPI in 2H25 under the "anti-involution&quo......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Fluß schwillt nicht an, ohne trübe zu werden. - Sprichwort Frankreich
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!